CTSO - CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer | Benzinga
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the re-appointment of Kathleen P. Bloch as full-time Chief Financial Officer, effective retroactively to September 2, 2023. Ms. Bloch served as the Company's Chief Financial Officer for 10 years until her retirement in March 2023, when she became Interim CFO as a consultant. She resumed as Interim CFO after the investigation of, and mutual termination and release agreement with, former CFO Alexander D'Amico, as detailed here and here, respectively.
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "Following this unexpected turn of events, it is great to have Kathy back as full-time Chief Financial Officer. Kathy's accomplished career speaks for itself as discussed here and here. We thank Kathy for her unquestioned dedication to the Company, the management team, and our employees over the past decade, and particularly now as we enter this exciting time for the Company. Kathy's commitment secures this leadership position and provides the time and expertise to focus and execute upon our critical near-term business goals and priorities."
Ms. Bloch stated, "The next six to twelve months is expected to bring a potential wealth of opportunities as we target U.S. and Canadian approval for the first time with DrugSorb®-ATR, and we work to capitalize on both anticipated improvements in the acute care markets and investments made with our existing CytoSorb® business. Like the rest of this outstanding team, I am passionate about our mission to help save lives and am proud of the Company we have built to date. It was an easy decision to come back and ...